Distribution kinetics of a micelle-forming block copolymer Pluronic P85

被引:102
作者
Batrakova, EV
Li, S
Li, YL
Alakhov, VY
Elmquist, WF
Kabanov, AV [1 ]
机构
[1] Univ Nebraska, Ctr Med, Coll Pharm, Dept Pharmaceut Sci, Omaha, NE 68198 USA
[2] Supratek Pharma Inc, Quebec City, PQ H9S 1A9, Canada
[3] Univ Minnesota, Dept Pharmaceut, Minneapolis, MN 55455 USA
关键词
biodistribution; micelles; P-glycoprotein; pluronic; polymer; pharmacokinetics;
D O I
10.1016/j.jconrel.2004.09.002
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Pluronic block copolymers, micelle-forming polymeric surfactants, are currently being evaluated in chemotherapy clinical trials in combination with doxombicin to treat multidrug-resistant (MDR) tumors. This study examines the pharmacokinetics and biodistribution of Pluronic P85 (P85), a potent inhibitor of P-glycoprotein (Pgp). P85 was radioactively labeled and administered intravenously (i.v.) to mice. The concentration of the copolymer was varied to examine the effects of micelle formation on the distribution kinetics. The main pharmacokinetic parameters (the area under the curve, half-life, clearance, mean residence time, and volume of distribution) were determined. The results suggest that half-life of P85 varies from 60 to 90 h, depending on its aggregation state. Formation of micelles decreased the uptake of the block copolymer in the liver. However, it had no effect on the total clearance, suggesting that the elimination of P85 was controlled by the renal elimination of P85 unimers and not by the rate of micelle disposition or disintegration. The total clearance value suggests that a significant portion of P85 is reabsorbed back into the blood, probably through the kidney's tubular membranes. (C) 2004 Elsevier B.V. All rights reserved.
引用
收藏
页码:389 / 397
页数:9
相关论文
共 36 条
[1]   Block copolymer-based formulation of doxorubicin. From cell screen to clinical trials [J].
Alakhov, V ;
Klinski, E ;
Li, SM ;
Pietrzynski, G ;
Venne, A ;
Batrakova, E ;
Bronitch, T ;
Kabanov, A .
COLLOIDS AND SURFACES B-BIOINTERFACES, 1999, 16 (1-4) :113-134
[2]   Hypersensitization of multidrug resistant human ovarian carcinoma cells by pluronic P85 block copolymer [J].
Alakhov, VY ;
Moskaleva, EY ;
Batrakova, EV ;
Kabanov, AV .
BIOCONJUGATE CHEMISTRY, 1996, 7 (02) :209-216
[3]   Drug delivery systems: Entering the mainstream [J].
Allen, TM ;
Cullis, PR .
SCIENCE, 2004, 303 (5665) :1818-1822
[4]   Effects of pluronic p85 on GLUT1 and MCT1 transporters in the blood-brain barrier [J].
Batrakova, EV ;
Zhang, Y ;
Li, YL ;
Li, S ;
Vinogradov, SV ;
Persidsky, Y ;
Alakhov, VY ;
Miller, DW ;
Kabanov, AV .
PHARMACEUTICAL RESEARCH, 2004, 21 (11) :1993-2000
[5]  
Batrakova EV, 2001, J PHARMACOL EXP THER, V296, P551
[6]   Effects of pluronic P85 unimers and micelles on drug permeability in polarized BBMEC and Caco-2 cells [J].
Batrakova, EV ;
Han, HY ;
Miller, DW ;
Kabanov, AV .
PHARMACEUTICAL RESEARCH, 1998, 15 (10) :1525-1532
[7]   Nephron number, renal function, and arterial pressure in aged GDNF heterozygous mice [J].
Cullen-McEwen, LA ;
Kett, MM ;
Dowling, J ;
Anderson, WP ;
Bertram, JF .
HYPERTENSION, 2003, 41 (02) :335-340
[8]   Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP 1049C) in patients with advanced cancer [J].
Danson, S ;
Ferry, D ;
Alakhov, V ;
Margison, J ;
Kerr, D ;
Jowle, D ;
Brampton, M ;
Halbert, G ;
Ranson, M .
BRITISH JOURNAL OF CANCER, 2004, 90 (11) :2085-2091
[9]   PHYSIOLOGICAL-PARAMETERS IN LABORATORY-ANIMALS AND HUMANS [J].
DAVIES, B ;
MORRIS, T .
PHARMACEUTICAL RESEARCH, 1993, 10 (07) :1093-1095
[10]   Ultrasound-enhanced tumor targeting of polymeric micellar drug carriers [J].
Gao, Zhonggao ;
Fain, Heidi D. ;
Rapoport, Natalya .
MOLECULAR PHARMACEUTICS, 2004, 1 (04) :317-330